Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
QuVa Pharma has added another forward distribution center to its existing 503B sterile injectable compounded medications platform. Quva now has two dedicated forward distribution facilities, with the new 20,000 sq. ft. distribution facility in Sugar ...
read more
Wednesday, April 29, 2020
A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials has been announced by Quotient Sciences and CytoAgents.
read more
Quotient Sciences announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people ...
read more
Monday, February 13, 2023
Quotient Sciences announced that it has completed an expansion of its early-phase formulation development capabilities for oral dosage forms at its Nottingham, UK, facility.
read more
Quotient Sciences, a drug development and manufacturing accelerator, completed major investments and expansions at its Nottingham, UK and Reading, UK, facilities to support the delivery of fully integrated drug development programs through the ...
read more
Tuesday, October 16, 2018
Quotient Sciences announces an expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa.
read more
Wednesday, December 12, 2018
Quotient Sciences announced a collaboration to utilize Quotient’s integrated Translational Pharmaceutics platform to advance the development of DRGT-46.
read more
Thursday, February 17, 2022
Quotient Sciences has integrated drug substance into its flagship Translational Pharmaceutics® platform. The newly integrated service unites drug substance, drug product and clinical testing activities all within a unified organization and under a ...
read more
Quotient Sciences announced the appointment of Thierry Van Nieuwenhove as its new Chief Executive Officer (CEO), effective 16th October 2023.
read more
Quotient Sciences has announced the appointment of Claes Glassell as non-executive chairman of its board of directors.
read more
Quotient Sciences, the drug development and manufacturing accelerator, announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, U.K. The investment will significantly expand Quotient’s drug substance ...
read more
Wednesday, September 11, 2024
VS-041, a novel and potentially life-saving treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology company, has reached a major clinical milestone with the first human subjects dosed at Quotient Sciences’ ...
read more
Monday, December 08, 2025
Quotient Sciences and Intrepid Labs announced a multi-year strategic partnership to advance the use of artificial intelligence (AI) in early drug development.
read more
Tuesday, September 02, 2025
Quotient Sciences and UK technology innovation center, CPI, have signed a memorandum of understanding (MoU) to form a Joint Venture (JV) aimed at accelerating the development of RNA-based therapies.
read more
Tuesday, October 14, 2025
Quotient Sciences and Biorasi have announced a strategic partnership aimed at streamlining early phase clinical trials from Investigational New Drug (IND) applications to patient proof-of-concept (POC) milestones.
read more